Peptide STAT Inhibitor Disrupts Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STAT inhibitors primarily target upstream kinases, lacking direct and selective inhibition of STAT proteins, which is necessary for effectively addressing aberrant activation in tumors.
Innovation Solution
Development of a peptide or peptidomimetic comprising the amino acid sequence of the second helix of STAT proteins, or variants thereof, that binds to and inhibits STAT proteins, particularly targeting the N-terminal domain to disrupt dimerization, tetramerization, and DNA interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current STAT inhibitors target upstream kinases, then the inhibition approach is established, but the selectivity and directness of STAT inhibition is reduced
Solution Approach 1:
The patent extracts the critical functional region (second helix) from the full STAT protein sequence to create a peptide inhibitor that specifically targets and inhibits STAT proteins. This extraction approach allows direct inhibition of STAT without requiring upstream kinase targeting, thereby improving selectivity and simplifying the inhibition mechanism.
Solution Approach 2:
The patent focuses on a specific local region (the second helix, residues 11-22) of the STAT protein, which is responsible for dimerization and DNA binding. By targeting this specific local region with a peptide inhibitor, the patent achieves high selectivity for STAT inhibition while maintaining a simple and direct mechanism of action.
2Reliability
If peptide inhibitors are designed to bind STAT proteins, then direct inhibition is achieved, but the complexity of peptide design and characterization increases
Solution Approach 1:
The patent segments the STAT protein into functional regions, focusing on the second helix (residues 11-22) for inhibitor design. This segmentation approach simplifies peptide synthesis by limiting the sequence to a specific functional region rather than the entire protein, making manufacturing more feasible while maintaining direct inhibition capability.
Solution Approach 2:
The patent employs peptidomimetic compounds that modify the physical and chemical parameters of the peptide sequence to enhance binding affinity and stability with STAT proteins. These parameter changes in the peptide structure improve direct inhibition effectiveness while managing the complexity of synthesis and characterization.
Data Source
AI summary
A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.